Johnson & Johnson has announced the FDA approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery. TECNIS PureSee IOL will be available for patients in the US later this year.
“Today marks an exciting milestone for people living with cataracts,” said Peter Menziuso, Company Group Chairman, Vision, Johnson & Johnson. “Cataract surgery is often a once-in-a-lifetime opportunity for patients to restore and enhance their vision. With the addition of TECNIS PureSee IOL to our portfolio, we can help even more patients regain not just sight, but the quality, range, and visual performance they expect from a Johnson & Johnson product.”
In a single procedure, TECNIS PureSee IOL addresses both cataract-related vision loss and the effects of presbyopia. Currently, an estimated 94 million people aged 50 and over have moderate-to-severe distance vision impairment or blindness that could be corrected through lens replacement surgery.
The PureSee IOL is the first and only FDA‑approved EDOF IOL with no warning on loss of contrast sensitivity. Aspheric monofocal IOLs are widely considered the benchmark for preserving contrast sensitivity, and by maintaining contrast sensitivity comparable to an aspheric monofocal IOL, TECNIS PureSee IOL helps patients experience the visual clarity and confidence they expect, while also benefiting from an extended range of vision, according to Johnson & Johnson.
TECNIS PureSee IOL is built on the TECNIS platform, combining advanced optics with proprietary material. It mitigates the effects of presbyopia by providing extended depth of focus, enabling excellent distance and intermediate vision, with some near vision. TECNIS PureSee IOL reduces patients’ reliance on glasses following surgery, with 97% of patients reporting no very bothersome visual disturbances.
Click here for media release
“Today marks an exciting milestone for people living with cataracts,” said Peter Menziuso, Company Group Chairman, Vision, Johnson & Johnson. “Cataract surgery is often a once-in-a-lifetime opportunity for patients to restore and enhance their vision. With the addition of TECNIS PureSee IOL to our portfolio, we can help even more patients regain not just sight, but the quality, range, and visual performance they expect from a Johnson & Johnson product.”
In a single procedure, TECNIS PureSee IOL addresses both cataract-related vision loss and the effects of presbyopia. Currently, an estimated 94 million people aged 50 and over have moderate-to-severe distance vision impairment or blindness that could be corrected through lens replacement surgery.
The PureSee IOL is the first and only FDA‑approved EDOF IOL with no warning on loss of contrast sensitivity. Aspheric monofocal IOLs are widely considered the benchmark for preserving contrast sensitivity, and by maintaining contrast sensitivity comparable to an aspheric monofocal IOL, TECNIS PureSee IOL helps patients experience the visual clarity and confidence they expect, while also benefiting from an extended range of vision, according to Johnson & Johnson.
TECNIS PureSee IOL is built on the TECNIS platform, combining advanced optics with proprietary material. It mitigates the effects of presbyopia by providing extended depth of focus, enabling excellent distance and intermediate vision, with some near vision. TECNIS PureSee IOL reduces patients’ reliance on glasses following surgery, with 97% of patients reporting no very bothersome visual disturbances.
Click here for media release
